SCHEMBL29081982

SCHEMBL29081982

CC1CCC(c2ccc3cnccc3c2)=NC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCZ Q05513 2/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ PRMT3 O60678 2/20 0.37
▸ TDO2 P48775 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ BRD4 O60885 1/20 0.35
▸ CREBBP Q92793 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ CDK8 P49336 2/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ AR P10275 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ IKBKB O14920 1/20 0.35
▸ SMYD3 Q9H7B4 1/20 0.34
▸ FASN P49327 1/20 0.34
▸ CYP11B1 P15538 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30470736 1.00 PRKCZ (0.38) PRKCZALOX15PRMT3TDO2GSK3B
SCHEMBL25320632 0.82 MAOA (0.43) GSK3BCYP11B1CYP11B2
SCHEMBL31578497 0.82 MAOA (0.43) GSK3BCYP11B1CYP11B2
SCHEMBL25320626 0.82 MAOA (0.43) GSK3BCYP11B1CYP11B2
SCHEMBL25323438 0.77 NOS3 (0.42) MAPK14
SCHEMBL24365080 0.77 NOS3 (0.42) MAPK14
SCHEMBL25335444 0.76 NOS3 (0.34) CYP11B1CYP11B2
SCHEMBL25335450 0.76 NOS3 (0.34) CYP11B1CYP11B2
SCHEMBL24233735 0.75 ALDH1A1 (0.54) ALOX15CDK8CYP11B1CYP11B2
SCHEMBL25323561 0.75 ALDH1A1 (0.54) ALOX15CDK8CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 PRKCZ 2902/4885ALOX15 922/4885PRMT3 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback